The marketing approach to determining the main indicators of economic efficiency of a hepatotropic drug
DOI:
https://doi.org/10.24959/sphhcj.18.123Keywords:
cost-effectiveness of the project, comprehensive marketing research, development of a new drug, hepatotropic drugs, expansion of the assortment, availability of drugsAbstract
Aim. To substantiate the expediency of development of an arginine-based hepatotropic drug using prognostic determination of the main indicators of economic efficiency.
Materials and methods. The legislative and regulatory base, data of the Morion information and retrieval system for 2013-2017, special literature and the results of the authors’ previous studies were used. The cost and rentability (R) of the drug manufacture, the amount of cash flows in three main variants of the project development, the discounted pay-back period (DPB) and the return on investment (ROI) were calculated. The historical, logical, marketing, and mathematical-statistical methods of research were used.
Results. Development of new drugs requires large amounts of money (from tens or hundreds of millions to 1-3 billion USD) for a significant period of time (from 3-4 to 10-14 years). The availability of the population to a drug increases in conditions of its sufficient production and prices acceptable to consumers. This is ensured by the presence of several manufacturers of a similar drug at the market. Arginine-based drugs have been found to have a wide range of pharmacological effects, forming a large potential volume of the market segment of the drug. The basic indicators of the economic efficiency of development of the arginine-based drug and marketing indicators of the market characteristics of the drug have been determined. Cash flows of income have been analyzed; and the terms of the return of discounted investments into the project in three variants of development of market events have been determined. The results of calculations on the basis of the marketing approach to the comprehensive market analysis of the characteristics of the arginine-based drug have confirmed the economic efficiency and investment attractiveness of the project.
Conclusions. The research on determining of the main indicators of the project economic efficiency has shown the feasibility of developing and introducing the arginine-based drug into the production assortment, as well as investment attractiveness of the project.
References
Zhadko, S. V., Slobodianiuk, M. M. (2008). Proceeding from Efektyvnist vykorystannia marketyngu ta logistyky farmatsevtychnymy organizatsiiamy: materialy naukovo–praktychnoi konferentsii (21 zhovtnia 2008) (pp. 147–152). Kharkiv.
Slobodianiuk, M. M., Samborskyi, O. S. (2018). Proceeding from Sotsialna farmatsiia: stan, problemy ta perspektyvy: materialy IV mizhnarodnoi naukovo–praktychnoi internet–konferentsyi (24 – 25 kvitnia 2018) (pp. 168–171). Kharkiv.
Slobodianiuk, M. M., Zhadko, S. V. (2008). Otsinka pryvablyvosti segmentu rynku likarskykh preparativ pry formuvanni tovarnoho asortymentu farmatsevtychnogo pidpryemstva. Kharkiv, 28.
Slobodianiuk, M. M., Zhadko, S. V., Samborskyi, O. S. (2010). Ukrainskyi zhurnal klinichnoi ta laboratornoi medytsyny, 2, 58–62.
Baigush, Yu. V., Slobodianiuk, M. M., Samborskyi, O. S. (2016). Proceeding from Upravlinnia yakistiu v farmatsii: zbirnyk naukovykh robit X naukovo–praktychnoi konferentsii z mizhnarodnoiu uchastiu (20 travnya 2016) (pp. 18–20). Kharkiv.
Slobodianiuk, M. M., Samborskyi, O. S., Hermanovski, T. (2017). Sotsialna farmatsiia v okhoroni zdorovia, 3 (4), 19–31. doi: 10.24959/sphhcj.17.95.
Slobodianiuk, M. M., Samborskyi, O. S. (2017). Proceeding from Upravlinnia yakistiu v farmatsii: materialy XI naukovo–praktychnoi konferentsii (19 travnia 2017) (pp. 161). Kharkiv.
Slobodianiuk, M. M., Samborskyi, O. S. (2017). Proceeding from Sotsialna farmatsiia: stan, problemy ta perspektyvy: materialy III mizhnarodnoi naukovo–praktychnoi internet–konferentsii (25–28 kvitnia 2017) (pp. 180–183). Kharkiv.
Posylkina, O. V. (2003). Visnyk farmatsii, 2 (34), 68–72.
Slobodianiuk, M. M., Samborskyi, O. S. (2016). Proceeding from Suchasni dosyagnennia farmatsevtychnoi texnolohii ta biotexnolohii: materialy V naukovo–praktychnoi internet–konferentsii z mizhnarodnoiu uchastiu (18 lystopada 2016) (pp. 557–560). Kharkiv.
Slobodianiuk, M. M., Samborskyi, O. S. (2016). Teoretychni osnovy ta metodyka obgruntuvannia efektyvnosti i investytsiinoi pryvablyvosti rozrobok ta vprovadzhennia likarskykh zasobiv na osnovi proektnogo planuvannia ta kompiuternoi obrobky. Kyiv, 36.
Kovalenko, Sv. M. (2015). Visnyk farmatsii, 4 (84), 47–51.
Slobodianiuk, M. M., Samborskyi, O. S., Hermanovski, T. (2017). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (52), 50–58. doi : 10.24959/uekj.17.32.
Samborskyi, O. S., Slobodianiuk, M. M. (2018). Proceeding from Aktualni pytannia suchasnoi medytsyny i farmatsii (do 50–ty richchia zasnuvannia ZDMU): materialy vseukrainskoi naukovo–praktychnoi konferentsii (17–18 travnia 2018) (pp. 169–170). Zaporizhzhia.
Samborskyi, O. S., Slobodianiuk, M. M., Yevtushenko O. (2017). The scientific heritage, 9 (9), 26–35.
Samborskyi, O. S., Slobodianiuk, M. M. (2017). Proceeding from Relevant issues of modern medicine: the experience of Poland and Ukraine: International research and practice conference (20–21 October 2017) (pp.127–129). Lublin.
Posylkina, O. V. (2004). Visnyk farmatsii, 3 (39), 59–62.
Demkyn, Y. V., Streltszov, A. V., Haletov, Y. D. (2004). Upravlenie riskom, 4, 16–27.
Nemchenko, A. S., Nazarkina, V. M. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 3 (41), 38–43.
Malyi, V. V., Samborskyi, O. S., Slobodianiuk, M. M. et al. (2018). Proceeding from Menedzhment ta marketyng u skladi suchasnoi ekonomiky, nauky, osvity, praktyky: materialy VI mizhnarodnoi naukovo–praktychnoi dystantsiinoi konferentsii (22–23 bereznia 2018) (pp. 7–41). Kharkiv.
Barratt, Michael J., Frail, Donald E. (Eds.). (2012). Drug repositioning: bringing new life to shelved assets and existing drugs. Wiley, 470.
Ding, M., Eliashberg, J., Stremersch, St. (2014). Marketing in the Pharmaceutical Industry. Chapter 3. Portfolio Management in New Drug Development. New York, 83–117.
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10 (2), 107–142.
Usherenko, S. V., Chernenko, D. D. (2015). Chasopys ekonomichnykh reform, 2 (18), 92–98.
DiMasi, J. A., Hansen, R. W., Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22 (3), 141–185.
Khonl, T. A. (2013). Problemy ucheta i finansov, 2 (10), 52–54.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
